Joshua Anderson

Myriad Genetics' Wild Ride: False Assumptions Whipsaw Stock

If you're a stockholder of Myriad Genetics (NASDAQ:MYGN) you're probably feeling a little queasy right now and wondering why the stock is now falling fast after initially reacting positively to Thursday's Supreme Court Decision. After all, the ruling in Association for Molecular Pathology v. Myriad Genetics Inc. was exactly what most observers and analysts expected. A reasonable investor would think that this outcome would already be factored into the stock price, but most analysts were sticking to their outperform ratings on the stock after the decision, only to reverse course and downgrade the stock after it fell in Thursday and Friday's sessions.

So what went wrong? Where was the disconnect between what the Street expected and what actually...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details